# Mirati Therapeutics (stock symbol: MRTX) Logo in transparent PNG and SVG formats

## Mirati Therapeutics Logo large

### Mirati Therapeutics Logo large Download PNG (23.33 KB)

![Mirati Therapeutics Logo large Download PNG (23.33 KB)](/img/orig/MRTX_BIG-b6678df6.png)

### Mirati Therapeutics Logo large Download SVG (4.09 KB)

![Mirati Therapeutics Logo large Download SVG (4.09 KB)](/img/orig/MRTX_BIG-64d1a42d.svg)

## Mirati Therapeutics Logo icon format

### Mirati Therapeutics Logo icon format Download PNG (29.12 KB)

![Mirati Therapeutics Logo icon format Download PNG (29.12 KB)](/img/orig/MRTX-eeefce5a.png)

### Mirati Therapeutics Logo icon format Download SVG (441 Bytes)

![Mirati Therapeutics Logo icon format Download SVG (441 Bytes)](/img/orig/MRTX-96709036.svg)

## Mirati Therapeutics Logo large for dark backgrounds

### Mirati Therapeutics Logo large for dark backgrounds Download PNG (23.33 KB)

![Mirati Therapeutics Logo large for dark backgrounds Download PNG (23.33 KB)](/img/orig/MRTX_BIG.D-8d89d16b.png)

### Mirati Therapeutics Logo large for dark backgrounds Download SVG (4.09 KB)

![Mirati Therapeutics Logo large for dark backgrounds Download SVG (4.09 KB)](/img/orig/MRTX_BIG.D-0bd033a7.svg)

## Mirati Therapeutics Logo icon format for dark backgrounds

### Mirati Therapeutics Logo icon format for dark backgrounds Download PNG (29.12 KB)

![Mirati Therapeutics Logo icon format for dark backgrounds Download PNG (29.12 KB)](/img/orig/MRTX.D-f336b33e.png)

### Mirati Therapeutics Logo icon format for dark backgrounds Download SVG (441 Bytes)

![Mirati Therapeutics Logo icon format for dark backgrounds Download SVG (441 Bytes)](/img/orig/MRTX.D-1de2f558.svg)

## About Mirati Therapeutics

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

1. Website domain: mirati.com
2. Employees: 413
3. Marketcap: $2.57 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
